Heme oxygenase-1 deficiency leads to alteration of soluble guanylate cyclase redox regulation

Journal of Pharmacology and Experimental Therapeutics

Volumn 335, Issue 1, 2010, Pages 85-91

  Jones, Allan W ^a,b   Durante, William ^a   Korthuis, Ronald J ^a,b  

^a University of Missouri   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ACETYLCHOLINE; BAY 602770; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; HEME OXYGENASE 1; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; UNCLASSIFIED DRUG; CELL RECEPTOR; ENZYME INHIBITOR; HEME; NITRIC ACID DERIVATIVE; NITRIC OXIDE DONOR; SOLUBLE GUANYLYL CYCLASE; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERANCE; IC 50; ISCHEMIA; KNOCKOUT MOUSE; MOUSE; NITRATE TOLERANCE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RENAL ARTERY; REPERFUSION INJURY; SUPERIOR MESENTERIC ARTERY; THORACIC AORTA; VASCULAR LESION; VASCULAR RING; VASOCONSTRICTION; VASODILATATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTERY; BIOSYNTHESIS; DEFICIENCY; DRUG EFFECTS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUSCLE RELAXATION; OXIDATION REDUCTION REACTION; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE;

ACETYLCHOLINE; ANIMALS; ARTERIES; BLOTTING, WESTERN; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GUANYLATE CYCLASE; HEME; HEME OXYGENASE-1; MICE; MICE, KNOCKOUT; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; NITRATES; NITRIC OXIDE DONORS; NITROPRUSSIDE; OXIDATION-REDUCTION; PHENYLEPHRINE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 77957234852     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.169755     Document Type: Article

References (36)

1. Ahluwalia A, Foster P, Scotland RS, McLean PG, Mathur A, Perretti M, Moncada S, and Hobbs AJ (2004) Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci USA 101:1386-1391.
2. Andresen JJ, Shafi NI, Durante W, and Bryan RM Jr (2006) Effects of carbon monoxide and heme oxygenase inhibitors in cerebral vessels of rats and mice. Am J Physiol Heart Circ Physiol 291:H223-H230.
3. Bennett BM, Schröder H, Hayward LD, Waldman SA, and Murad F (1988) Effect of in vitro organic nitrate tolerance on relaxation, cyclic GMP accumulation, and guanylate cyclase activation by glyceryl trinitrate and the enantiomers of isoidide dinitrate. Circ Res 63:693-701.
4. Duckers HJ, Boehm M, True AL, Yet SF, San H, Park JL, Clinton Webb R, Lee ME, Nabel GJ, and Nabel EG (2001) Heme oxygenase-1 protects against vascular constriction and proliferation. Nat Med 7:693-698.
5. Durante W, Johnson FK, and Johnson RA (2006) Role of carbon monoxide in cardiovascular function. J Cell Mol Med 10:672-686.
6. Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HH, and Stasch JP (2006) NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5:755-768. (Pubitemid 44323702)
7. Franke R, Yang Y, Rubin LJ, Magliola L, and Jones AW (2004) High-fat diet alters K+-currents in porcine coronary arteries and adenosine sensitivity during metabolic inhibition. J Cardiovasc Pharmacol 43:495-503.
8. Friebe A and Koesling D (2003) Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res 93:96-105. (Pubitemid 36919696)
9. Fukuda S, Matsumoto M, Nishimura N, Fujiwara N, Shimoji K, Takeshita H, and Lee TJ (1990) Endothelial modulation of norepinephrine-induced constriction of rat aorta at normal and high CO2 tensions. Am J Physiol 258:H1049-H1054.
10. Hoffmann LS, Schmidt PM, Keim Y, Schaefer S, Schmidt HH, and Stasch JP (2009) Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation. Br J Pharmacol 157:781-795.
11. Kim HP, Ryter SW, and Choi AM (2006) CO as a cellular signaling molecule. Annu Rev Pharmacol Toxicol 46:411-449.
12. Knorr A, Hirth-Dietrich C, Alonso-Alija C, Härter M, Hahn M, Keim Y, Wunder F, and Stasch J-P (2008) Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. Arzneimittelforschung 58:71-80.
13. Korthuis RJ and Durante W (2005) Heme oxygenase-1: a pluripotent sentinel limiting the systemic inflammatory response to extremity ischemia and reperfusion. Crit Care Med 33:2701-2703.
14. Krieg T, Liu Y, Rütz T, Methner C, Yang XM, Dost T, Felix SB, Stasch JP, Cohen MV, and Downey JM (2009) BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts. Eur Heart J 30:1607-1613.
15. Magliola L and Jones AW (1990) Sodium nitroprusside alters Ca 2+ flux components and Ca2+-dependent fluxes of K + and Cl- in rat aorta. J Physiol 421:411-424.
16. Mergia E, Friebe A, Dangel O, Russwurm M, and Koesling D (2006) Spare guanylyl cyclase NO receptors ensure high NO sensitivity in the vascular system. J Clin Invest 116:1731-1737.
17. Meurer S, Pioch S, Pabst T, Opitz N, Schmidt PM, Beckhaus T, Wagner K, Matt S, Gegenbauer K, Geschka S, et al. (2009) Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation. Circ Res 105:33-41.
18. Mullershausen F, Russwurm M, Friebe A, and Koesling D (2004) Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272. Circulation 109:1711-1713.
19. Münzel T, Daiber A, and Mülsch A (2005) Explaining the phenomenon of nitrate tolerance. Circ Res 97:618-628.
20. Münzel T, Daiber A, Ullrich V, and Mülsch A (2005) Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase. Arterioscler Thromb Vasc Biol 25:1551-1557.
21. Münzel T, Genth-Zotz S, and Hink U (2007) Targeting heme-oxidized soluble guanylate cyclase: solution for all cardiorenal problems in heart failure? Hypertension 49:974-976. (Pubitemid 351664319)
22. Naik JS and Walker BR (2006) Role of vascular heme oxygenase in reduced myogenic reactivity following chronic hypoxia. Microcirculation 13:81-88.
23. Ndisang JF, Zhao W, and Wang R (2002) Selective regulation of blood pressure by heme oxygenase-1 in hypertension. Hypertension 40:315-321. (Pubitemid 35006717)
24. Poss KD and Tonegawa S (1997) Heme oxygenase 1 is required for mammalian iron reutilization. Proc Natl Acad Sci USA 94:10919-10924.
25. Pyriochou A and Papapetropoulos A (2005) Soluble guanylyl cyclase: more secrets revealed. Cell Signal 17:407-413. (Pubitemid 39643059)
26. Roy B, Mo E, Vernon J, and Garthwaite J (2008) Probing the presence of the ligand-binding haem in cellular nitric oxide receptors. Br J Pharmacol 153:1495-1504.
27. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, et al. (2001) NO-independent regulatory site on soluble guanylate cyclase. Nature 410:212-215. (Pubitemid 32216593)
28. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H S AK, Meurer S, Deile M, Taye A, Knorr A, Lapp H, et al. (2006) Targeting the heme-oxidized nitric oxide receptor for selective vasodilation of diseased blood vessels. J Clin Invest 116: 2552-2561.
29. True AL, Olive M, Boehm M, San H, Westrick RJ, Raghavachari N, Xu X, Lynn EG, Sack MN, Munson PJ, et al. (2007) Heme oxygenase-1 deficiency accelerates formation of arterial thrombosis through oxidative damage to the endothelium, which is rescued by inhaled carbon monoxide. Circ Res 101:893-901.
30. Vanhoutte PM (1989) Endothelium and control of vascular function. State of the Art lecture. Hypertension 13:658-667.
31. Wiesel P, Patel AP, Carvajal IM, Wang ZY, Pellacani A, Maemura K, DiFonzo N, Rennke HG, Layne MD, Yet SF, et al. (2001) Exacerbation of chronic renovascular hypertension and acute renal failure in heme oxygenase-1-deficient mice. Circ Res 88:1088-1094.
32. Wolin MS (2009) Reactive oxygen species and the control of vascular function. Am J Physiol Heart Circ Physiol 296:H539-H549.
33. Wu L and Wang R (2005) Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. Pharmacol Rev 57:585-630.
34. Yet SF, Layne MD, Liu X, Chen YH, Ith B, Sibinga NE, and Perrella MA (2003) Absence of heme oxygenase-1 exacerbates atherosclerotic lesion formation and vascular remodeling. FASEB J 17:1759-1761.
35. Yet SF, Pellacani A, Patterson C, Tan L, Folta SC, Foster L, Lee WS, Hsieh CM, and Perrella MA (1997) Induction of heme oxygenase-1 expression in vascular smooth muscle cells. A link to endotoxic shock. J Biol Chem 272:4295-4301.
36. Yet SF, Perrella MA, Layne MD, Hsieh CM, Maemura K, Kobzik L, Wiesel P, Christou H, Kourembanas S, and Lee ME (1999) Hypoxia induces severe right ventricular dilation and infarction in heme oxygenase-1 null mice. J Clin Invest 103:R23-R29.